{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:07:10Z","timestamp":1791648430466,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We aimed to estimate the overall incidence of safety events in patients with UC in a real-life population cohort for comparison with the tofacitinib UC clinical trial program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical trial-like criteria were applied to an IBM MarketScan\u00ae claims database population-based cohort (n = 22,967) of patients with UC (October 2010 to September 2015) to identify a UC trial-like cohort treated with tumor necrosis factor inhibitors (TNFi; n = 6366) to compare with the tofacitinib UC clinical trial cohort (n = 1157).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Incidence rates (events per 100 patient-years; [95% confidence interval]) in the UC trial-like cohort were as follows: serious infections, 3.33 (2.73\u20134.02); opportunistic infections (OIs; excluding herpes zoster [HZ]), 1.45 (1.06\u20131.93); HZ, 1.77 (1.34\u20132.29); malignancies (excluding nonmelanoma skin cancer [NMSC]), 0.63 (0.43\u20130.90); NMSC, 1.69 (1.35\u20132.10); major adverse cardiovascular events (MACE), 0.51 (0.31\u20130.79); pulmonary embolism (PE), 0.54 (0.30\u20130.89); deep vein thrombosis (DVT), 1.41 (1.00\u20131.93); and gastrointestinal perforations, 0.31 (0.16\u20130.54). Compared with the UC trial-like cohort, tofacitinib-treated patients had numerically lower incidence rates for serious infections (1.75 [1.27\u20132.36]), OIs (excluding HZ; 0.16 [0.04\u20130.42]), NMSC (0.78 [0.47\u20131.22]), PE (0.16 [0.04\u20130.41]), and DVT (0.04 [0.00\u20130.23]), and a higher rate for HZ (3.57 [2.84\u20134.43]); rates for malignancies (excluding NMSC), MACE, and gastrointestinal perforations were similar.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>When acknowledging limitations of comparing claims data with controlled clinical trial data, incidence rates for HZ among TNFi-treated patients in the UC trial-like cohort were lower than in the tofacitinib UC clinical trial cohort; rates for serious infections, OIs, NMSC, PE, and DVT were numerically higher.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov<\/jats:title>\n                  <jats:p>NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izaa289","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T09:53:18Z","timestamp":1608112398000},"page":"1394-1408","source":"Crossref","is-referenced-by-count":33,"title":["Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan\u00ae Administrative Claims Database With Tofacitinib Trial Data"],"prefix":"10.1093","volume":"27","author":[{"given":"Jeffrey R","family":"Curtis","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham , Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic , Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Yun","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham , Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyu","family":"Su","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nervin","family":"Lawendy","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chudy I","family":"Nduaka","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Koram","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Groton, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Modesto","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine of the University of Pennsylvania , Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2023112500150068400_CIT0001","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/MIB.0000000000001261","article-title":"Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis","volume":"23","author":"Cross","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2023112500150068400_CIT0002","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1185\/03007995.2015.1065242","article-title":"Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database","volume":"31","author":"McAuliffe","year":"2015","journal-title":"Curr Med Res Opin."},{"key":"2023112500150068400_CIT0003","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2015.284","article-title":"Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a Nationwide Danish Cohort Study 1977-2013","volume":"110","author":"Kants\u00f8","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"2023112500150068400_CIT0004","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2023112500150068400_CIT0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2023112500150068400_CIT0006","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MIB.0000000000000243","article-title":"Cancer and immunomodulators in inflammatory bowel diseases","volume":"21","author":"Biancone","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2023112500150068400_CIT0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112500150068400_CIT0008","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2023112500150068400_CIT0009","doi-asserted-by":"crossref","first-page":"571","DOI":"10.14309\/00000434-201810001-00571","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: an interim analysis of an open-label, long-term extension study with up to 4.9 years of treatment (abstract)","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2023112500150068400_CIT0010","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112500150068400_CIT0011","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-0038-1673354","article-title":"Truven health analytics MarketScan databases for clinical research in colon and rectal surgery","volume":"32","author":"Kulaylat","year":"2019","journal-title":"Clin Colon Rectal Surg."},{"key":"2023112500150068400_CIT0012","author":"IBM Watson Health","year":"2019"},{"key":"2023112500150068400_CIT0013","author":"Janssen","year":"2019"},{"key":"2023112500150068400_CIT0014","author":"US Food and Drug Administration","year":"2018"},{"key":"2023112500150068400_CIT0015","volume-title":"Interpretation and Use of Medical Statistics","author":"Daly","year":"1991","edition":"4th ed"},{"key":"2023112500150068400_CIT0016","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0010-4825(92)90023-G","article-title":"Simple SAS macros for the calculation of exact binomial and Poisson confidence limits","volume":"22","author":"Daly","year":"1992","journal-title":"Comput Biol Med."},{"key":"2023112500150068400_CIT0017","author":"Howlader"},{"key":"2023112500150068400_CIT0018","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/apt.14420","article-title":"Long-term safety of adalimumab in clinical trials in adult patients with Crohn\u2019s disease or ulcerative colitis","volume":"47","author":"Colombel","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112500150068400_CIT0019","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."},{"key":"2023112500150068400_CIT0020","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1038\/ctg.2016.24","article-title":"Maintenance of efficacy and continuing safety of golimumab for active ulcerative colitis: PURSUIT-SC maintenance study extension through 1 year","volume":"7","author":"Gibson","year":"2016","journal-title":"Clin Transl Gastroenterol."},{"key":"2023112500150068400_CIT0021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies","volume":"18","author":"Reinisch","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2023112500150068400_CIT0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology."},{"key":"2023112500150068400_CIT0023","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"key":"2023112500150068400_CIT0024","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"key":"2023112500150068400_CIT0025","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"key":"2023112500150068400_CIT0026","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2023112500150068400_CIT0027","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2023112500150068400_CIT0028","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112500150068400_CIT0029","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/pds.3310","article-title":"Validation of acute myocardial infarction in the Food and Drug Administration\u2019s Mini-Sentinel program","volume":"22","author":"Cutrona","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2023112500150068400_CIT0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/pds.4398","article-title":"Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database","volume":"27","author":"Ammann","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2023112500150068400_CIT0031","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.conctc.2018.11.001","article-title":"Validation of a claims-based algorithm identifying eligible study subjects in the ADAPTABLE pragmatic clinical trial","volume":"12","author":"Fishman","year":"2018","journal-title":"Contemp Clin Trials Commun."},{"key":"2023112500150068400_CIT0032","first-page":"e374","article-title":"Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts","volume":"24","author":"Govani","year":"2018","journal-title":"Am J Manag Care."},{"key":"2023112500150068400_CIT0033","doi-asserted-by":"crossref","first-page":"e000155","DOI":"10.1136\/bmjgast-2017-000155","article-title":"Prevalence and screening for anaemia in mild to moderate Crohn\u2019s disease and ulcerative colitis in the United States, 2010-2014","volume":"4","author":"Akhuemonkhan","year":"2017","journal-title":"BMJ Open Gastroenterol."},{"key":"2023112500150068400_CIT0034","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/9\/1394\/53788245\/izaa289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/9\/1394\/53788245\/izaa289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:29:52Z","timestamp":1700872192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/27\/9\/1394\/6039005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa289","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2020,12,16]]}}}